A mixed methods study examining insulin pump management in pediatric type 1 diabetes reveals significant gaps in addressing pump-related skin complications. Caregivers reported skin complications in 42.0% of children using insulin pumps, yet management approaches remained largely empirical without standardized protocols. The research simultaneously surveyed caregivers, healthcare professionals, and manufacturer technical support staff, uncovering a knowledge-practice gap rooted in structural barriers including role ambiguity and absent evidence-based guidelines. The findings indicate that responsibility for skin management lacks clear ownership across stakeholder groups. To address these deficiencies, the authors recommend formally integrating skin management into pediatric diabetes care protocols with explicitly assigned multidisciplinary roles. Educational interventions should shift from single-point delivery to longitudinal, reinforcement-based models combining theory with practice. Additionally, manufacturer technical support staff should have formalized roles in training pathways with clear disclosure requirements. The study emphasizes the urgent need for international, evidence-based guidelines developed through collaboration among endocrinologists, dermatologists, nurses, and device manufacturers to prevent and manage skin complications in children using continuous subcutaneous insulin infusion therapy.

GLP-1 medications for weight loss commonly cause gastrointestinal side effects including reflux, diarrhea, constipation, and nausea during the adjustment period. According to endocrinologist Dr. Keren Zhou, these effects occur because GLP-1 medications slow gastric emptying and gut motility, affecting how food moves through the digestive system. To manage these side effects, Dr. Zhou recommends several strategies. Before starting or increasing dosage, patients should eat lighter meals in the preceding 24 hours to avoid feeling sick once the medication slows digestion. Subsequently, patients must adapt to smaller meal portions since the stomach's reduced capacity can cause nausea and reflux if overwhelmed. Eating smaller, more frequent meals allows the stomach adequate time to digest between meals, helping mitigate digestive discomfort. Additionally, avoiding trigger foods that are high in fat, fiber, or sugar during the adjustment phase can further reduce symptoms. Understanding how GLP-1 medications affect digestion empowers patients to make informed dietary choices that minimize side effects while successfully losing weight.

Eli Lilly and Company offers two distinct assistance programs to improve patient access to Mounjaro, a GLP-1 medication for weight loss. The Lilly Cares Foundation Patient Assistance Program, a 501(c)(3) nonprofit separate from Lilly's commercial operations, provides Mounjaro at no cost for up to twelve months to eligible uninsured U.S. residents earning at or below 400% of the federal poverty level ($63,840 annually for individuals, $132,000 for families of four as of 2026). Approved patients must reapply annually, though coverage details remain unclear as sources disagreed in 2026 regarding Mounjaro's inclusion on the medication list. The Mounjaro Savings Card serves patients with commercial insurance facing high copayments, allowing eligible individuals to pay as little as $25 per supply. These programs target different populations: the Savings Card excludes government insurance holders due to federal anti-kickback regulations, while Lilly Cares is reserved for uninsured patients without alternative coverage options. This dual-program approach addresses affordability barriers for distinct patient groups seeking GLP-1 therapy.

# Professional Summary Wegovy injections demonstrate excellent tolerability when administered correctly, with the STEP clinical trials encompassing 4,567 patients providing robust safety evidence for semaglutide 2.4 mg. Seventy-three percent of patients reported only mild injection-site reactions, and remarkably, just 0.1% discontinued treatment due to injection pain. The research reveals that reported discomfort stems primarily from injection technique errors—such as excessive speed, striking muscle, or injecting into tensed tissue—rather than the medication itself. Pain alone was reported by only 4.2% of semaglutide patients compared to 1.9% receiving placebo saline injections, indicating that approximately half of reported pain is mechanical rather than chemical. Severe reactions occurred in just 0.3% of cases, predominantly involving nodules or bruising rather than pain. Three key variables significantly influence patient comfort: injection speed, needle technique, and tissue preparation. Wegovy's once-weekly auto-injector pen delivery over five to ten seconds produces substantially lower pain rates than daily insulin injections in type 1 diabetes, which range from twelve to eighteen percent. These findings demonstrate that proper administration technique substantially minimizes discomfort and supports high treatment adherence rates among patients using GLP-1 therapy.

Living with diabetes extends far beyond glucose monitoring, encompassing a complex bidirectional relationship between blood sugar management and mental health. Fluctuations in blood glucose levels directly impact cognitive function and concentration, while emotional challenges such as depression and anxiety can undermine self-care behaviors and medication adherence. The daily demands of diabetes management—involving repeated decisions about food, medication, sleep, and exercise—can accumulate into emotional fatigue over time. Recognizing this interconnection, current clinical guidance, including recommendations from the American Diabetes Association Professional Practice Committee (2024), now emphasizes psychosocial health and behavioral assessment as integral components of diabetes care. Research, including studies by McCrimmon et al. (1999), demonstrates that hypoglycemic episodes affect cognitive performance variably across individuals. Successful diabetes management therefore requires holistic support addressing both metabolic control and psychological well-being, with screening protocols to identify patients requiring additional mental health support. This integrated approach enables healthcare teams and families to provide more effective, person-centered care that recognizes the profound impact of emotional well-being on treatment outcomes.

Effective July 1, 2026, the Centers for Medicare & Medicaid Services launched the Medicare GLP-1 Bridge program, a short-term demonstration initiative designed to expand access to glucagon-like peptide-1 medications for weight management among Medicare beneficiaries. The program, administered by CMS in coordination with UnitedHealthcare and patient pharmacies, currently covers specific GLP-1 medications while excluding others such as Ozempic, Rybelsus, Mounjaro, and Trulicity. Eligible patients generally include those meeting specific clinical criteria, with CMS determining individual eligibility through a streamlined process that typically requires minimal direct provider engagement with CMS, though prior authorization forms may be necessary. Prescribers should anticipate seeing prescriptions processed through this new pathway when treating qualifying Medicare patients. This initiative represents a significant policy shift addressing the growing demand for weight management pharmacotherapy among Medicare populations, improving accessibility to approved GLP-1 treatments while maintaining oversight through standard review mechanisms. Healthcare providers can access detailed guidance through CMS's official resources or contact the dedicated email support at glp1demo@cms.hhs.gov.

Diabetes distress is a clinically recognized emotional condition affecting up to forty-five percent of people with diabetes, characterized by the cumulative burden of managing more than one hundred and eighty daily health-related decisions. This specific emotional response—manifesting as worry, frustration, exhaustion, and overwhelm tied directly to diabetes management—differs fundamentally from clinical depression or general anxiety disorders because it is situational and improves when management demands become more manageable. Researchers William Polonsky and Lawrence Fisher developed the Diabetes Distress Scale (DDS-17), a validated seventeen-item screening tool enabling clinicians to measure and identify this condition, which has long remained underdiagnosed and underaddressed in clinical practice. Unlike depression, which requires distinct treatment approaches, diabetes distress responds effectively to evidence-based psychological interventions including Cognitive Behavioral Therapy and Acceptance and Commitment Therapy when these directly target the chronic disease self-management burden. Recognizing diabetes distress as a legitimate clinical phenomenon rather than personal failure represents a critical shift in patient care, as addressing the underlying management demands is essential to alleviating this pervasive emotional toll that significantly impacts quality of life.

GLP-1 and GLP-1/GIP dual agonist medications offer significant benefits for diabetes management, including improved glucose control, A1C reduction, enhanced heart health, better sleep, and weight loss support. However, accessing these medications requires strategic navigation. This guide outlines a three-step process for patients: first, establish personal health goals using the SMART goal framework and communicate priorities to healthcare providers; second, discuss medication options with your HCP to identify the most suitable treatment aligned with insurance coverage; and third, request a prescription from an FDA-approved pharmacy such as CVS, Walgreens, or Amazon Pharmacy, requesting assistance with prior authorization if needed. The article emphasizes avoiding non-FDA-approved compounded versions available through third-party sellers due to safety risks, instead recommending FDA-approved options and established patient assistance programs. Patient advocacy and persistence are essential when navigating potential coverage barriers, as healthcare providers can help identify safe, effective access routes tailored to individual needs.

# Summary A qualitative research study conducted in Kenya examined the acceptability, feasibility, and user experiences of continuous glucose monitoring (CGM) technology among individuals with Type 1 diabetes across multiple stakeholder groups. The research gathered perspectives from adolescents, young adults, caregivers, and healthcare providers to understand how CGM devices are perceived and utilized in the Kenyan healthcare context. The study explores practical challenges and benefits associated with implementing CGM technology in a resource-limited setting, where diabetes management infrastructure remains underdeveloped. Participants provided insights into usability, cost considerations, cultural factors, and integration into daily diabetes care routines. The findings highlight both the potential advantages of CGM technology for improving glycemic control and the significant barriers to adoption, including affordability and technical support. This research is important for understanding how continuous glucose monitoring can be effectively implemented in sub-Saharan African contexts and informs policy decisions regarding diabetes management strategies in low-resource healthcare environments.

Glucagon-like peptide-1 drugs like Ozempic and Mounjaro have transformed weight management for millions, but stopping their use presents significant challenges. Following Oprah Winfrey's publicized experience of regaining weight after discontinuation, researchers increasingly recognize the complexities of GLP-1 cessation. According to Professor Roy Taylor at Newcastle University, patients discontinue these medications for varied reasons: cost constraints, intolerable side effects including nausea and gastrointestinal issues, or even emotional attachment to appetite suppression. Beyond physical factors, Taylor notes unusual psychological barriers, including relationship pressures and loss of confidence following dramatic transformations. The fundamental challenge stems from GLP-1s' mechanism: they mimic natural appetite-suppressing hormones, so cessation rapidly restores baseline hunger levels and triggers weight regain. Users frequently experience improved physical vigor, reduced inflammation, and decreased cravings for alcohol and substances during treatment. Understanding why patients struggle to maintain weight loss post-treatment matters substantially for developing sustainable interventions and managing patient expectations, ultimately improving long-term health outcomes in obesity management.

Self-injection is essential for millions managing diabetes, hormone therapy, autoimmune conditions, and fertility treatments, yet many patients experience unnecessary discomfort due to inadequate technique guidance. This comprehensive guide synthesizes evidence-based methods for minimizing injection pain across three distinct phases: before, during, and after administration. Injection discomfort originates from three sources: needle penetration, medication deposition, and muscle reaction. Key controllable factors include allowing refrigerated medications to reach room temperature over twenty to thirty minutes rather than heating them artificially, applying ice packs for fifteen minutes beforehand to numb the injection site, and using topical lidocaine creams approximately thirty minutes prior. During injection, technique matters significantly—avoiding rapid plunger pushes, ensuring complete alcohol evaporation before needle insertion, and maintaining a relaxed muscle all reduce pain. Post-injection soreness can be minimized by preventing site overuse and ensuring proper medication dispersal. The guidance emphasizes that these evidence-based techniques supplement rather than replace healthcare provider instructions. By addressing these controllable variables—needle sharpness, medication temperature, injection speed, and site preparation—patients can transform self-injection from a frequently uncomfortable experience into a nearly painless routine.

Comprehensive diabetes care requires addressing mental health as a critical component, particularly in Savannah where regional factors intensify disease management challenges. The relationship between diabetes and mental health is bidirectional: chronic illness increases depression and anxiety risk, while untreated mental health conditions elevate type 2 diabetes risk. Physiologically, chronic stress triggers cortisol release, increasing insulin resistance and blood glucose levels, directly undermining treatment adherence. The American Psychological Association has documented how stress hormones disrupt diabetes management. Beyond clinical depression, diabetes distress—a distinct condition characterized by emotional exhaustion from continuous disease monitoring—affects many patients. In Savannah specifically, traditional Southern dietary culture centered on sweet tea and fried foods, combined with coastal Georgia's oppressive heat limiting outdoor exercise opportunities, intensifies these psychological burdens. Effective diabetes care must therefore integrate mental health support as an essential pillar, recognizing that emotional well-being directly impacts glycemic control and long-term health outcomes. Healthcare providers in Savannah must understand local contexts to deliver truly comprehensive patient support.

The transition from pediatric to adult diabetes care represents a critical challenge for young people with diabetes, often resulting in deteriorating blood glucose control, missed appointments, and increased risk of complications. While adolescents typically thrive under pediatric diabetes programs that offer coordinated, family-centered care with multidisciplinary teams including endocrinologists, educators, dietitians, and psychologists, adult healthcare systems demand greater individual responsibility. Research demonstrates that HbA1c levels frequently rise during the first years after transfer, with increases in hospitalizations for diabetic ketoacidosis and emergency department visits, particularly among those aged eighteen to twenty-five. This decline extends beyond clinical factors; young adulthood coincides with major life disruptions including college enrollment, employment, independent living, insurance coverage changes, and reduced parental involvement in medication management. Understanding these transition barriers is essential for patients, families, and clinicians to develop strategies that maintain glycemic control and prevent complications. Solutions increasingly involve technology integration and coordinated care models that bridge the gap between pediatric and adult healthcare systems, supporting young adults through this vulnerable period of diabetes management.

Type 2 diabetes and hypertension represent critical public health challenges in sub-Saharan Africa, yet treatment outcomes remain suboptimal due to poor patient adherence. This comprehensive systematic review and meta-analysis synthesized adherence data across medication, lifestyle, and self-monitoring interventions from 312 studies encompassing 108,014 participants across 28 sub-Saharan African countries. The research revealed concerning adherence gaps: antidiabetic medication adherence reached 67%, antihypertensive medications only 51%, while dietary adherence was 44% and physical activity adherence 42%. Self-monitoring rates were particularly low at 18% for glucose monitoring and 28% for blood pressure monitoring. Overall self-care adherence averaged merely 37% for diabetes and 35% for hypertension. Network analysis identified education, self-efficacy, and social support as critical cross-cutting determinants most strongly associated with improved adherence. These findings underscore the urgent need for targeted interventional strategies addressing these priority factors to enhance treatment control and clinical outcomes across the region.

A nurse-led digital therapeutics pathway for type 2 diabetes management demonstrated superior outcomes compared to usual care in a 24-week retrospective cohort study involving 113 adults. The structured pathway incorporated digital readiness assessment, onboarding education, adherence monitoring, tiered follow-up, feedback reports, and physician-technical staff coordination. Patients in the nurse-led pathway achieved 78.3% adherence to digital therapeutics compared to 54.7% in usual care, representing a 23.6 percentage point difference. Mean glycated hemoglobin improved by 0.8% in the nurse-led group versus 0.3% in usual care. Additionally, the intervention was associated with higher patient satisfaction scores on the PSQ-18 scale, improved self-management behaviors, and reduced glycemic variability. Pathway exposure remained the strongest predictor of sustained engagement after statistical adjustment. These findings suggest that integrating nurse-led support with digital therapeutics addresses critical challenges in diabetes management—extending self-management beyond clinic visits and sustaining patient engagement. However, the authors acknowledge limitations inherent to single-center retrospective design and recommend prospective multicenter trials before establishing causal relationships or implementing broad clinical adoption.

GLP-1 agonists, including popular brands like Ozempic and Wegovy, have gained significant attention as weight-loss medications despite being originally developed for type 2 diabetes management. These drugs work by slowing digestion and increasing satiety, enabling users to consume fewer calories and achieve average weight loss of 15% of body weight. However, according to Dr. Regina Ragasa, a lifestyle medicine specialist at Kaiser Permanente, this efficacy comes with important caveats. Most patients regain 60-70% of lost weight within a year of discontinuing the medication, underscoring that sustainable results require concurrent lifestyle modifications. Additionally, GLP-1s are relatively new pharmaceuticals with emerging concerns about side effects that remain incompletely understood. Dr. Ragasa recommends exploring alternative approaches first, including lifestyle interventions and established medications like phentermine, which has decades of clinical experience supporting its safe and effective use in weight management. This measured perspective highlights the importance of balancing pharmaceutical convenience against long-term sustainability and safety considerations.

Novo Nordisk has announced significant pricing initiatives for Ozempic and Wegovy, both semaglutide-based GLP-1 receptor agonist treatments. New self-paying patients in the United States can access the two lowest doses for $199 monthly for the first two months, while existing self-pay patients will see prices reduced from $499 to $349 per month. Insurance coverage varies depending on whether plans are commercial, private, Medicare, Medicaid, or government-funded options. Patients can contact Novocare, Novo Nordisk's support program, to obtain personalized insurance cost estimates. While Ozempic is FDA-approved for diabetes management, off-label prescriptions for weight loss may not be covered by all insurance plans. In such cases, Wegovy, approved specifically for weight loss, or alternative treatments like Saxenda (liraglutide) may be considered. Patients should consult their healthcare providers and insurance plans to identify which weight loss treatments are covered under their specific policies.

Insulin injection site rotation is a critical practice for patients requiring long-term insulin therapy. Repeatedly injecting insulin at the same location causes lipohypertrophy—lumps of fatty tissue—a complication affecting approximately 47% of insulin users worldwide. Because injecting into lipohypertrophic areas is less painful than healthy skin, patients often develop habitual injection patterns that perpetuate tissue damage. Regular site rotation prevents lipohypertrophy development, maintains skin health, ensures consistent insulin absorption, and improves blood sugar control. Medical experts recommend four primary injection areas: the abdomen, thighs, upper arms, and buttocks. Each area absorbs insulin at different rates, making systematic rotation essential. Healthcare providers recommend dividing the abdomen into quadrants and other body areas into halves, then rotating in clockwise patterns before transitioning between regions. For patients administering multiple daily injections, tracking injection sites through records or mobile applications such as Insulin Site helps maintain adherence to rotation protocols and prevents repeated site use. This structured approach optimizes therapeutic outcomes and reduces injection-related complications.

Managing diabetes has transformed dramatically with innovations including continuous glucose monitors, automated insulin delivery systems, GLP-1 receptor agonists, and SGLT2 inhibitors. However, clinicians increasingly recognize that treatment burden—the physical, emotional, financial, and logistical demands of disease management—has emerged as a critical clinical outcome affecting adherence, glycemic control, and long-term patient outcomes. Treatment burden encompasses multiple responsibilities: taking multiple medications, monitoring blood glucose, managing insulin dosing, maintaining dietary changes, attending appointments, navigating insurance, and using diabetes technologies. When these cumulative demands exceed patients' capacity to manage them alongside work and other obligations, adherence declines and health outcomes worsen. As healthcare shifts toward person-centered care, providers are reconsidering their approach, asking not merely whether therapies lower A1C but whether patients can realistically sustain treatment over time. Understanding and reducing treatment burden has become essential to high-quality diabetes management, representing a fundamental shift in how clinicians evaluate therapy effectiveness and design individualized treatment plans.

A multimodal M-Stim device reduced progression to cLBP significantly more than TENS. Both devices reduced pain initially, but M-Stim reduced pain and disability significantly more over time, particularly in cLBP subsets with higher severity, duration, or BMI.